Neon Therapeutics Inc. intends to file for an IPO of up to $115 million.
The company will list on the Nasdaq Global Market under the ticker NTGN.
The Cambridge, Mass.-based biotechnology company develops therapies that target neoantigens — abnormal proteins produced by cancer cells — and personalized T cell therapies. The company has a strategic collaboration with CRISPR Therapeutics AG.
Oppenheimer & Co. is the lead manager for the transaction. Bank of America Merrill Lynch, Mizuho Securities and Morgan Stanley serve as joint book-running managers.
